Kirk McPoyle Joins Clinical Ink as Chief Commercial Officer

PHILADELPHIA, PA & CAMBRIDGE, MA – October 18, 2016 –  Clinical Ink, the leading provider of eSource and mobile patient engagement technologies for clinical trials, announces the addition of Kirk McPoyle to its management team. He has joined Clinical Ink as the Chief Commercial Officer.

“Kirk has an excellent track record of driving growth for innovative clinical technology companies,” said CEO Ed Seguine. “His therapeutic area insights and consultative approach are perfect match with the capabilities of our eSource platform to improve protocol execution and deliver a better experience for sites, sponsors and patients. We’re excited for him to help support new and existing clients as the realize the benefits of eSource.”

“Over the years, I’ve seen a lot of industry change,” said Mr. McPoyle. “I believe Clinical Ink offers the most compelling and innovative clinical technology platform I’ve seen in this market. The company has grown quickly and established a solid customer base in both large and small pharma, and I’m excited to help accelerate this growth.”

Mr. McPoyle most recently led Business Development at Acurian, where he developed the commercial strategy that saw the company grow revenues 10x prior to a strategic acquisition by PPD. Mr. McPoyle comes to Clinical Ink with over 25 years of business development and marketing experience with CROs, patient recruitment, business intelligence, and pharma companies and joins the company during a period of major expansion and growth.

Since its commercial launch in 2012, Clinical Ink has emerged as an innovation leader with its eSource and patient engagement platform. The SureSource platform eliminates the need for separate EDC, eCOA, and ePRO applications while reducing the cost, complexity, and time associated with data management and monitoring activities. SureSource collects documents and data from sites and patients in real time, providing sponsors with timely, data-based insights into protocol execution, data quality, trial surveillance, and GCP compliance that are impossible with legacy EDC/eCOA/ePRO systems and current practices.

 

About Clinical Ink

Founded in 2007, Clinical Ink® is transforming clinical development with innovative technologies that make clinical research easier for sites, sponsors and patients. Clinical Ink’s SureSource® platform directly captures eSource data and documents and improves patient engagement while streamlining clinical development. Clinical Ink maintains offices in Cambridge, MA, Winston-Salem, NC, and Philadelphia, PA.

Media Contact: Rob Quinn | 336.728.6830 | rob.quinn@clinicalink.com